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Abstract
Purpose. MDM2 is an oncogene whose protein product may promote tumorigenesis by blocking wild-type p53 tumor
suppressor mediated G0/G1 cell cycle arrest, thereby inhibiting repair of damaged DNA prior to cell division. While
MDM2 DNA ampli® cation is frequently observed in human sarcoma, the mechanisms linking this ampli® cation to MDM2
oncoprotein over-production as well as its functional signi® cance have not been well characterized in patients with soft
tissue sarcoma.
Methods. A tissue bank of resected soft tissue sarcomas and autologous normal tissues was assembled; all specimens were
snap frozen within 15 min of resection. DNA and RNA were extracted from tissues using isoamyl alcohol and phenol
chloroform extraction methods, respectively; cell lysates were prepared using PBSTDS lysis buffer. DNA and mRNA were
con® rmed as being non-degraded and were then examined for MDM2 DNA ampli® cation (Southern blots) and mRNA
over-expression (Northern blots) using actin (DNA) and glyceraldehyde-3-phosphate dehydrogenase (mRNA) as loading
controls. The MDM2 protein was examined on Western blots using the MDM2-speci® c monoclonal antibody IF2
(Oncogene Science, Inc). The presence of p53 DNA and expression of p53 mRNA was examined by rehybridizing the
Southern and Northern ® lters using a p53-speci® c cDNA probe.
Results. Soft tissue sarcomas and autologous normal tissues were screened for MDM2 DNA ampli® cation, which was
detected in 10 of 30 tumors screened. After screening, there was suf® cient biomaterials from six specimens for subsequent
Northern and Western analysis to see whether MDM2 gene ampli® cation correlated with over-expression of MDM2
mRNA and MDM2 protein. In addition, we examined whether other mechanisms may lead to over-expression of the
MDM2 oncoprotein. Several possible mechanisms of MDM2 oncoprotein over-expression were identi® ed. These most
commonly included MDM2 DNA ampli® cation, MDM2 mRNA over-expression and MDM2 oncoprotein over-ex-
pression. However, some soft tissue sarcoma patient specimens had no evidence of MDM2 mRNA over-expression yet had
MDM2 oncoprotein over-production in the tumor relative to autologous normal tissue, implying possible post-transcrip-
tional regulation. Of functional relevance, MDM2 oncoprotein over-production by tumors was associated with large
decreases in the percentage of cells in the G0/G1 cell cycle interface compared with autologous normal tissue cells.
Discussion. It is likely that there are multiple mechanisms underlying human soft tissue sarcoma MDM2 oncoprotein
over-production. Consequently, strategies that decrease MDM2 over-production, such as transcriptional repression to
inhibit MDM2 promoter activity or RNA antisense approaches, may ultimately offer the best therapeutic ef® cacy.
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Introduction
The MDM2 oncogene codes for a 90-kDa protein
may be involved in regulation of tumor proliferation
via suppression of wild-type (wt) p53 mediated G1
cell cycle checkpoint control.
1,2 MDM2 can over-
come wt p53 suppression of transformed cell
growth,
3 most likely by forming a complex with wt
p53
4 and thereby concealing the wt p53 activation
domain.
5 Experimentally induced DNA damage
increases levels of MDM2 mRNA in cells expressing
wt p53;
6 wt p53 may transcriptionally activate the
MDM2 gene.
7,8 These interactions suggest an au-
toregulatory feedback loop in which wt p53 protein
regulates the MDM2 gene at the transcriptional level
and MDM2 protein regulates wt p53 protein at the
activity level.
9,10 This autoregulatory network as elu-
cidated in the above cell line experimentation sug-
gests that the coordinate presence of mutated p53
and MDM2 would be redundant in suppressing G1
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checkpoint control.
9 Consistent with this, most in-
itial tumor tissue observations have failed to detect
MDM2 gene ampli® cation in the presence of
mutated p53 gene.
9
MDM2 oncoprotein inactivation of tumor sup-
pressor gene function may also alternatively involve
physical and functional interaction with RB, the
protein product of the retinoblastoma tumour sup-
pressor gene, thereby inhibiting RB-mediated tumor
growth regulation.
11 Moreover, the MDM2 onco-
protein may not only release a tumor proliferative
control by blocking p53 and RB, but may also
positively augment tumor proliferation by stimulat-
ing the cell cycle S-phase inducing transcription
factors E2F1/DP1.
12 Studies in MDM2-de® cient
mice have provided important insights regarding the
interaction of MDM2 and p53 in vivo.
13,14 MDM2
null mice are not viable; however, MDM2 null
lethality is avoidable in mice that are also p53 null,
suggesting a critical in vivo role of MDM2 as
a negative regulator of p53 function in normal
development.
14
Mechanisms underlying the production of
MDM2 protein in tumor tissue have not yet been
fully characterized. However, MDM2 gene am-
pli® cation has been described in a variety of tumors















and germ cell tumors,
29 and as an especially
frequent ® nding in soft tissue sarcoma.
30
In light of these considerations, we sought to
analyze MDM2 in soft tissue sarcoma and au-
tologous normal tissue at the DNA, RNA and pro-
tein levels to delineate possible mechanisms
underlying sarcoma over-production of MDM2
oncoprotein. Our studies suggest several patterns of
regulation including MDM2 gene ampli® cation,
possible transcriptional and post-transcriptional
regulation, and coordinate presence of MDM2 gene
ampli® cation with possible p53 gene mutation,
a ® nding not anticipated by the MDM2± p53
autoregulatory loop hypothesis.
Patients and methods
Tissue acquisition and preservation
Soft tissue sarcoma, autologous normal skeletal
muscle resected as part of the surgical specimens
and autologous peripheral blood lymphocytes were
retrieved, fast-frozen in liquid nitrogen, and stored
in a 2 140°C freezer for subsequent usage. These
tissues were acquired as part of a clinical research
protocol approved by the University of Texas MD
Anderson Cancer Center Surveillance Committee
(Institutional Review Board).
DNA analysis
High molecular weight DNA from normal and tu-
mor samples was extracted by proteinase K diges-
tion and phenol/chloroform extraction. A 2.2-kb
human MDM2 fragment and a 1.8-kb human p53
fragment were used as probes in Southern blot
analyses. A b -actin probe was used as an internal
loading control. Both the human MDM2 and p53
plasmids were provided as a kind gift by Dr B.
Vogelstein. For the Southern blot analysis, 20 m g of
genomic DNA were digested with EcoRI restriction
endonuclease overnight and then electrophoretically
separated on 0.8% agarose gel and blotted to nylon
membranes. The membranes were prehybridized
with 1 3 Church buffer at 65°C for 1 h and hy-
bridized with the MDM2 DNA probe that had been
labeled at 65°C overnight with [
32P]dCTP using a
random primer DNA labeling kit (Boeringer
Mannheim Corp., Indianapolis, IN, USA). Mem-
branes were then washed and subjected to autora-
diography at 2 80°C for 4± 20 h using intensifying
screens. The same membranes were then washed
twice with 0.1% sodium dodecyl sul® de followed by
0.1X SSC at 100°C for 20 min for each wash and
then rehybridized with the human p53 and b -actin
probes.
mRNA analysis
Total cellular RNA was extracted directly from snap
frozen tumor specimens using a guanidinium
thiocyanate± hot phenol method as described pre-
viously.
31 For Northern blot analyses, Poly(A
1 )
RNA was prepared by oligo(dT)-cellulose chro-
matography, fractionated on 1% denaturing
formaldehyde± agarose gels, electrotransferred at
0.6 A to a GeneScreen nylon membrane (DuPont
Co., Boston, MA, USA) and UV cross-linked with
120 000 m J cm
2 2 using a UV Stratalinker 1800
(Stratagene, La Jolla, CA, USA). Filters were
washed two or three times at 60°C with 30 mM
NaCl-3 mM sodium citrate (pH 7.2)± 0.1%
NaDodSO4 (w/v). A glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe was used as a load-
ing control. The cDNA probes used were a 2.2-kb
restriction endonuclease fragment from the plasmid
corresponding to the full length MDM2 human
cDNA.
Cellular protein analysis
Western blot analyses of autologous sarcoma and
normal tissues were performed as previously de-
scribed.
32 The nitrocellulose membrane was blocked
with 2% non-fat milk in TPBS buffer (0.05%
Tween-20 in phosphate-buffered salup (PBS)
buffer) for 1 h and then incubated with 1 m g ml
2 1 of
MDM2-speci® c monoclonal antibody Ab IF2
(Oncogene Science, Inc., Uniondale, NY, USA).MDM2 oncoprotein expression in sarcomas 25
Fig. 1. Standard pattern of MDM2 oncoprotein over-production. DNA analysis demonstrates MDM2 gene ampli® cation. There
is MDM2 mRNA expression and increased MDM2 oncoprotein production relative to autologous normal tissue.
Fig. 2. Lack of MDM2 oncoprotein over-production. There is no detectable MDM2 gene ampli® cation or mRNA over-expression.
MDM2 oncoprotein production is equivalent in sarcoma and autologous normal tissue.
Fig. 3. MDM2 oncoprotein over-production: possible post-transcriptional regulation. While there is clear MDM2 DNA ampli® cation
in the tumor compared with autologous normal tissue, MDM2 mRNA does not appear to be over-expressed in the tumor. However,
there is obvious increased tumor MDM2 oncoprotein over-production.26 R. E. Pollock et al.
Fig. 4. MDM2 oncoprotein over-production: possible p53 mutations. The Southern analysis demonstrates MDM2 DNA
ampli® cation in tumor as well as a possible coexisting p53 mutation. Over-expressed mRNA and tumor over-production of MDM2
oncoprotein are also observable.
Fig. 5. Dysregulated cell-cycle kinetics in a sarcoma with MDM2 oncoprotein over-production. The standard pattern of MDM2
oncoprotein over-production is observed as per Fig. 1. The percentage of cells in the S 1 G2M phase is increased more than four-fold
in the sarcoma relative to the autologous normal tissue.
Flow cytometry
Disaggregated cells were adjusted to 1.0 3 10
6 cells/
ml for ¯ ow cytometric analysis of DNA content in
fresh tissues. A cytospin preparation was evaluated
for preparation quality and nuclear integrity. Cells
were subsequently stained with acridine orange us-
ing the standard two-step method. Ploidy status was
de® ned by the DNA index, which represents the
ratio of the relative G0/G1 diploid peak. Near-
diploid (hypodiploid or hyperdiploid) DNA was de-
termined after mixing a test sample with lymphocyte
controls.
Results
An initial screen of 30 resected soft tissue sarcomas
identi® ed 10 tumors with MDM2 amplication at the
DNA level. In several patients (predominantly
liposarcoma) there was suf® cient sarcoma as well as
autologous normal tissue to support a more exten-
sive analysis at the DNA, mRNA and cellular pro-
tein levels. Figure 1 is representative of the typical
pattern of MDM2 protein over-production in sar-
coma relative to that in autologous normal tissue:
MDM2 DNA ampli® cation in tumor (Southern
blot), abundant MDM2 mRNA (over) expression inMDM2 oncoprotein expression in sarcomas 27
the tumor (Northern blot) and MDM2 protein
over-expression by sarcoma (Western blot) com-
pared to the autologous normal tissue. In contrast,
Fig. 2 is representative of the more typical pattern
observed at the initial tumor screening: no sarcoma
MDM2 DNA ampli® cation, and equivalent levels of
MDM2 mRNA expression with comparable levels
of MDM2 protein production in both the sarcoma
and autologous normal tissues.
Figure 3 illustrates an alternative possible mech-
anism of MDM2 protein over-production by tumor.
While there is relative sarcoma MDM2 DNA am-
pli® cation, there is minimal if any detectable
MDM2 mRNA over-expression in the tumor. How-
ever, there is markedly increased MDM2 protein
production in the tumor relative to that in au-
tologous normal tissue, implying a possible MDM2
post-transcriptional level of regulatory control.
MDM2 may interact with p53 in an autoregula-
tory loop control process such that p53 protein
regulates the MDM2 gene at the level of transcrip-
tion, and MDM2 protein regulates the p53 protein
at the level of its activity.
9 Because this hypothesized
feedback loop regulates both the activity of the p53
protein as well as the expression of the MDM2 gene,
it would be redundant for a tumor to contain both
MDM2 gene ampli® cation and p53 gene mutations.
However, Fig. 4 illustrates the possibility that these
two alterations may coexist within a single sarcoma.
As depicted, there is MDM2 DNA ampli® cation in
the sarcoma relative to that seen in autologous nor-
mal tissue. In addition, there is a possible p53
mutation detectable in the sarcoma that is not de-
tected in the normal tissue. Both MDM2 and p53
mRNA transcripts were present, and there was rela-
tive MDM2 and p53 protein over-production in the
sarcoma tissues compared to the autologous control
tissues.
Lastly, we analyzed the potential functional
signi® cance of MDM2 protein over-production
given that MDM2 blockade of wt p53 leads to loss
of G0/G1 cell cycle arrest and a concomitant increase
in the percentage of cells in the S 1 G2M phase of
the cell cycle. Figure 5 depicts ¯ ow cytometry his-
tograms for a representative sarcoma and au-
tologous normal tissue where there was concomitant
sarcoma MDM2 DNA ampli® cation and MDM2
protein over-production. Cell cycle dysregulation is
suggested in that the normal tissue percentage of
cells in the G0/G1 cell cycle phase was 91.2% and
the S 1 G2M percentage was 8.8%, whereas the
comparable percentages in the sarcoma were 59.8%
and 40.2%, respectively.
Discussion
While MDM2 gene ampli® cation appears to be a
relatively common event in soft tissue sarcoma and
several other solid malignancies, the spectrum of









38 and esophageal carcinoma.
39 How-
ever, many studies have considered only MDM2
gene ampli® cations (Southern analysis) or, alterna-
tively, MDM2 protein production. This strategy
may miss possible translational or post-transcrip-
tional regulatory mechanisms; therefore, the spec-
trum of tumor involvement may perhaps be broader
than has been initially described.
In keeping with this possibility, Landers et al.
recently described experiments using two different
choriocarcinoma cell lines in which elevated MDM2
protein levels were not associated with gene am-
pli® cation or over-expression of MDM2 mRNA.
40
Instead, a post-transcriptional regulatory mechan-
ism was shown to be responsible for enhanced trans-
lation. Olson et al. demonstrated four other MDM2
protein forms (p85, p76, p74 and p58± p57) in
addition to p90 that were detected in a sponta-
neously transformed BALB/c mouse 3T3 cell line
using monoclonal and polyclonal antibodies gener-
ated against murine and human MDM2 proteins.
41
It is possible that these alternative proteins could
have arisen from various spliced mRNA forms of the
MDM2 gene or by post-translational MDM2 pro-
tein alterations.
41
Working with breast carcinoma cell lines, Sheikh
et al. demonstrated that the high constitutive
MDM2 mRNA levels observed in estrogen receptor
positive cells was the result of differential regulation
of the MDM2 gene at the transcriptional and/or
post-transcriptional level.
15 Similar post-transcrip-
tional regulatory mechanisms were also identi® ed in
studies involving breast carcinoma cell lines con-
ducted by Gudas et al.
42 However, to date, MDM2
post-transcriptional regulation has not been
analyzed in soft tissue sarcoma, perhaps because of
the relative rarity of the disease and the dif® culties
in extracting mRNA from sarcoma tissues.
30,43
Several studies have focused on the issue of con-
comitant MDM2 gene ampli® cation and p53 gene
mutation in soft tissue sarcoma. Leach et al. ana-
lyzed 24 soft tissue sarcomas, identifying eight tu-
mors with p53 mutations and a non-overlapping
subset of another eight sarcomas with MDM2 gene
ampli® cation (DNA analysis).
44 It was concluded
that p53 and MDM2 genetic alterations were
alternative mechanisms for inactivating the same
regulatory pathway and that double mutations in
both p53 and MDM2 were redundant and provided
no selective advantage over mutation in only one of
the two genes.
Cordon-Cardo et al. examined a larger selection
of soft tissue sarcomas using Southern analysis and
immunohistochemical analysis.
45 Seventy-six of 211
sarcomas had abnormally high levels of MDM2
protein; 56 of these 211 tumors over-expressed p53
proteins. Twenty-two of these 211 sarcomas had
abnormally high levels of both p53 and MDM228 R. E. Pollock et al.
proteins. These 22 patients had signi® cantly
impaired survival relative to the other individuals
studied. However, these immunohistochemical de-
terminations apparently did not include a direct
comparison of p53 and MDM2 protein status that
incorporated autologous normal control tissues. Be-
cause of possible differences between autologous
normal and sarcoma tissues, as we have detected in
the MDM2 Western analyses here, it is dif® cult to
conclude that the presence of immunohistochemical
positive staining for both p53 and MDM2 in
the same sarcoma sample means that there is a
coexisting double mutation of these respective
genes.
In this same analysis, over-expression of either
p53 or MDM2 protein on immunohistochemistry
did not always correlate with MDM2 gene am-
pli® cation or p53 gene mutation as determined by
DNA analysis. While 11 of 73 sarcomas had MDM2
ampli® cation interpreted as at least 5± 35 fold gene
copy excess, only six of these 11 tumors had in-
creased MDM2 protein. In contrast, 17 of 62 sarco-
mas with increased MDM2 protein lacked
detectable MDM2 gene ampli® cation.
These ® ndings suggest that there might be addi-
tional MDM2 gene mutations not detected by the
Southern analysis, or that the immunohistochemical
analysis did not detect the presence of one or an-
other of the alternative MDM2 protein forms. As an
additional possibility, post-transcriptional or post-
translational regulation may be operative, as is sug-
gested in Fig. 3, or perhaps MDM2 mRNA levels
were under-expressed. These latter possibilities
might be resolvable using an MDM2 mRNA ana-
lytic strategy.
Alternatively, since MDM2 over-expression is
suf® cient for inactivation of wt p53 function, the
possible double mutation of both p53 and MDM2
genes in the sarcoma depicted in Fig. 4 and the
analysis of Cordon-Cardo et al. suggests that there
might be a `gain of function’ in the development of
sarcoma. Additional studies, possibly utilizing co-
transfection strategies, will be required to address
this issue.
Florenes et al. examined 68 sarcomas, 26 human
sarcoma xenografts and two sarcoma cell lines for
MDM2 ampli® cation and p53 mutations in exons 5,
7 or 8, as well as p53 and MDM2 mRNA over-
expression.
46 They observed ampli® cation of the
MDM2 gene in 10 tumors, nine of which also had
MDM2 mRNA over-expression. However, MDM2
mRNA was also over-expressed in an additional
three sarcomas that lacked MDM2 gene am-
pli® cation. None of the tumors with MDM2 gene
ampli® cation had mutations detected in their re-
spective p53 genes. The presence of MDM2 or p53
protein product production was not examined in
this study. Taken together, these reports point to the
importance of experimental schema that consider
MDM2 and p53 status on the DNA, RNA and
protein levels in both sarcomas and paired
autologous tissues.
Therapeutic strategies to blunt the functional im-
pact of MDM2 gene ampli® cation that leads to
over-production of MDM2 oncoprotein will need to
account for the possibility of multiple regulatory
mechanisms, multiple oncoprotein products, and
the yet to be established potential interplay between
simultaneous MDM2 gene ampli® cation and p53
gene mutations. Transcriptional regulation, RNA
antisense approaches or even augmentation of wt
p53 cell cycle regulatory function in MDM2 am-
pli® ed tumors may prove to be feasible and of future
therapeutic bene® t for patients burdened by soft
tissue sarcoma.
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